Plasma cell leukemia
MONDO:0018689An aggressive plasma cell neoplasm characterized by the presence of neoplastic plasma cells in the peripheral blood. It is characterized by the presence of a circulating clonal plasma cell count that exceeds 2x10^9/L or is 20% of the leukocyte differential count.
Also known as: PCL, leukaemia plasmacytic, leukemia plasmacytic, plasma cell leukemia, plasmacytic leukaemia, plasmacytic leukemia, leukemia, plasma cell
2045 clinical trials for this condition and its sub-types, 32 tagged with Plasma cell leukemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New vaccine aims to train immune system against myeloma
Vaccine OngoingThis early-phase trial tests whether a vaccine made from a protein called survivin can safely boost the immune system to fight multiple myeloma. The study involves 18 patients who have already responded to initial treatment and are taking lenalidomide as maintenance therapy. The …
Phase 1 • Sponsor: Roswell Park Cancer Institute • Aim: Vaccine
Last updated Jun 27, 2026 12:32 UTC
-
New attack plan for rare leukemia: CAR-T cells + stem cell transplant
Disease control OngoingThis study tests a new treatment for a rare and aggressive blood cancer called primary plasma cell leukemia. The approach combines chemotherapy, a stem cell transplant, and two infusions of specially engineered immune cells (CAR-T cells) that target the cancer. The goal is to see…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug may make stem cell transplants safer for older patients
Disease control OngoingThis early-phase trial tests whether the drug itacitinib can prevent cytokine release syndrome (a severe inflammatory reaction) after a mini stem cell transplant in people aged 60 and older with certain blood cancers. The study also aims to see if itacitinib allows doctors to use…
Phase 1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 26, 2026 18:40 UTC
-
Cancer drug dose study canceled before it began
Knowledge-focused CancelledThis study was designed to find the safest and most effective dose of the chemotherapy drug bendamustine for people with multiple myeloma that had not been cured by earlier treatments. It was a Phase 1 trial, meaning it focused on side effects and dosing, not on curing the diseas…
Phase 1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC